Skip to content
The Nexus
BUSINESSJul 30 · 12:20 UTCQUARTZCris Tolomia

Bristol Myers Squibb is raising its full-year outlook after blood thinner sales surged past expectations

Bristol Myers Squibb is raising its full-year outlook after blood thinner sales exceeded expectations. Strong sales of Eliquis, Camzyos, and Reblozyl pushed second-quarter revenue to $12.97 billion, surpassing analyst estimates.

Nexus surfaces and summarizes. The full story lives at the source.

Mentioned
Bristol Myers SquibborganizationEliquistopicCamzyostopicReblozyltopicblood thinnertopic
Spot something wrong with this article?Report a problem →
Forward this
Related Signal

Adjacent reporting

Bristol Myers Squibb is raising its full-year outlook after blood thinner sales surged past expectations · The Nexus